Patient-derived xenograft models of breast cancer and their predictive power

Whittle, James R; Lewis, Michael T; Lindeman, Geoffrey J; Visvader, Jane E

doi:10.1186/s13058-015-0523-1

Breast Cancer Research

Table 1 Generation of orthotopic patient-derived xenografts from primary breast cancer and metastatic tissue

From: Patient-derived xenograft models of breast cancer and their predictive power

Study	Mouse strain	Supportive conditions	Stable take rate	Tissue source	IHC subtypes of PDX	Correlation with engraftment	PDX concordance with source tissue	Metastases
Al-Hajj and colleagues [23], Liu and colleagues [76]	NOD/SCID	Estradiol	NR	Primary breast (6)	4 TNC	NR	NR	5/8 (62%) micrometastases
	NSG	Etoposide i.p.		Pleural effusion (2)	2 HER2⁺
		Matrigel			2 ER⁺
Fleming and colleagues [36]	NOD/SCID	Estradiol	NR	TNC pleural effusion (2)	NR	Increased engraftment in abdominal versus thoracic mammary gland	NR	NR
		Etoposide i.p.
		Matrigel
DeRose and colleagues [25]	NOD/SCID	Estradiol	12/49 (27%)	Primary breast (4)	5 TNC	Similar engraftment for primary and metastatic tumors	Histological PAM 50 expression profiling	10/12 to lymph node, lung and peritoneum
				Pleural effusion (7)	2 HER2⁺	TNC grew fastest	Genomic
				Ascites (1)	3 ER⁺/HER2⁺	Increased tumor growth with serial passage
					2 ER⁺	Engraftment as a prognostic indicator of disease outcome
Vaillant and colleagues [30], Oakes and colleagues [35]	NSG	Estradiol	37/158 (23%)	Primary breast (37)	17 TNC	TNC and HER2⁺ higher engraftment	Histological	NR
					13 ER⁺
					2 ER⁻PR⁺
					5 HER2⁺
Ma and colleagues [58]	NOD/SCID	Fibroblasts^a	NR	Primary breast (1)	3 TNC	NR	PAM 50 expression profiling	NR
				Ovarian metastasis (1)			Genomic
				Brain metastasis (1)
Kabos and colleagues [37]	NOD/SCID	Estradiol		Primary breast (6)	2 TNC	Nonluminal higher take rate than luminal tumors	Histological	NR
	NSG	Matrigel	10/24 (42%)	Metastatic effusion (2)	8 ER⁺
Zhang and colleagues [32]	SCID/Bg	Estradiol	6/32 (19%) in NSG mice, 1/38 SCID/Bg (no E2), 1/29 SCID/Bg (E2 + fibroblasts), 15/70 (21%) SCID/Bg (E2)	Primary breast (22)	12 TNC	TNC and grade III have higher take rate	Histological	12/25 (48%) lung metastases
	NSG	Fibroblasts^a		Ascites (2)	3 HER2⁺		Clinical response
				Pleural effusion (1)	2 ER⁺
Li and colleagues [49]	NOD/SCID	Fibroblasts^a	22/152 (13%)	Primary breast	12 ER^/HER2⁻	NR	Histological	NR
				Nodal metastasis	2 HER2⁺		Immunohistochemical
				Skin metastases/recurrence	7 ER⁺/HER2⁻		Proteomic
					1 ER⁺/HER⁺		Genomic
Zhang and colleagues [71]	NOD/SCID	Matrigel	NR	Primary breast (6)	7 TNC	NR	Histological	NR
				Soft tissue metastasis (1)			Biomarker expression
							PIKC3A sequence
							Genomic

Bg, beige; E2, estradiol; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; IHC, immunohistochemistry; i.p., intraperitoneally; NSG, NOD/SCID/IL2γ-receptor null; NOD, nonobese diabetic; NR, not reported; PDX, patient-derived xenograft; PR, progesterone receptor; SCID, severe combined immunodeficiency; TNC, triple-negative cancer. ^aIrradiated and unirradiated for humanization.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com